A new type of Aa Glu-I 1 to Gly substitution has been identified in a congenitally abnormal fibrinogen, fibrinogen Mitaka ll, derived from a 14-year-old female suffering from easy bruising since childhood. Plasma of the patient and fibrinogen purified therefrom were found to clot slowly by thrombin but in a normal fashion by ancrod, a thrombin-like snake venom enzyme. The ancrod-clotted fibrin gels were normally solid and turbid, whereas the thrombin-clotted gels were initially fragile and transparent but became gradually normalized during further incubation. On reversephase high-performance liquid chromatography, there was an additional peptide group eluted distinctly later than the corresponding normal fibrinopeptide A in the clot-liquor of the patient's samples. Sequence analysis of these aberrant peptides and isolated Aa chains of the patient's IBRINOGEN IS CONVERTED to fibrin by thrombin-F catalyzed cleavage of a specific Arg-Gly peptide bond at positions 16 and 17 of the A a chain, for which efficient interactions between fibrinogen and thrombin are certainly Indeed, the fibrinogen-thrombin interactions have been studied extensively by determining the conserved sequences in fibrin~gen,~ kinetics and nuclear magnetic resonance (NMR) analyses using synthetic analogs of fibrinopeptide A (FPA),"' and more recently by crystallographic analyses on analogs of FPA or its related Aa (7-20) residue segment complexed with thr~mbin.'.'~ These studies unanimously showed that the first 6 residues of FPA are not involved in the interaction with thrombin, whereas the carboxyl-side Asp-7 to Arg-I6 residues, in particular, Asp-7, Phe-8, Glu-11, Gly-12, and Arg-16, are required for the binding of the peptide to thrombin. In fact, point mutations at positions 7, 12, and 16 to other amino acids have been shown in human hereditary dysfibrinogens associated with 0006-4971/93/8212-0029$3.00/0 fibrinogen showed that Glu at position 11 of the abnormal Aa chain had been replaced by Gly. Studies using '251-labeled thrombin showed that the binding with thrombin was evidently reduced for her fibrinogen and the aberrant fibrinopeptide A as compared with that for the normal controls, indicating that Aa Glu-I 1 may be critical for the fibrinogen-thrombin interaction. Indeed, Aa Glu-I 1 of fibrinogen has recently been proposed to stabilize the local conformation, including the @-turn, and to form a salt bridge between its side-chain carboxyl group and the guanidino group of Arg-I 73 of thrombin based on crystallographic analyses using analogs of fibrinopeptide A com- We herein report a new type of point mutation of Gly for Aa Glu-1 1, whose side chain carboxyl group has recently been proposed to form a salt bridge with the guanidino group of Arg-173 of
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The thrombin residue number is according to the chymotrypsinogen system."
MATERIALS AND METHODS
Coagulation studies. Coagulation studies were conducted according to standard procedures" or as described previou~ly.'~ Blood collection and fibrinogen pur&ation. Blood was collected from the patient and her parents, and anticoagulated with 1/9 vol of 3.8% trisodium citrate. Plasmas were harvested by centrifugation for 30 minutes at 3,000 rpm and 4°C. Portions of the plasma were deprived of fibronectin and plasminogen, and fibrinogen was purified therefrom by repeated 25% saturation with ammonium sulfate, pH 7.0, as described previo~sly.'~ Determination of protein concentrations. Extinction coefficients (E;:m at 280 nm) for calculating the protein concentration were 15.1 for fibrinogen"; and 1 1 3, 17.4, and 20.4 for the Aa, BP, and y chains of fibrinogen, respectively"; 18.3 for bovine a-thrombin2'; and 14.3 for y-glob~lin.~'
Clotting studies ofpurifiedfibrinogen andfibrin monomer aggregation. Thrombin was purified from a commercial bovine thrombin (Mochida Pharmaceutical Co, Tokyo, Japan) by the method of L~n d b l a d ?~ and ancrod, the purified fraction of a thrombin-like enzyme derived from Malayan pit viper, Agkistrodon rhodostoma, was a kind gift from Dr M. Fukuda (Mochida Pharmaceutical Co). The thrombin time and the ancrod time tests were performed as follows. To 0.2 mL of 1 mg/mL fibrinogen in 25 mmol/L imidazole-HCI, pH 7.4, containing I35 mmol/L NaCl (imidazole-buffered saline [IBS]), 0.1 mL of 4 National Institutes of Health (NIH) U/mL purified bovine thrombin or 4 U/mL ancrod in IBS with or without 25 mmol/L CaCI, was added, and the clotting time was measured in duplicate on a fibrometer (Becton Dickinson and Co, Cockeysville, MD), and the results were averaged. Fibrin monomer aggregation as monitored by absorbance at 350 nm (A35o) was conducted essentially according to Gralnick et aLZ5
The patient's fibrinogen was clotted with thrombin or ancrod as described previously,26 and the released FPA and FPB were analyzed by reverse-phase high performance liquid chromatography (HPLC) with a Cosmosil 5C18P column applying a gradient between 6% and 17% acetonitrile in 25 mmol/L ammonium acetate, ) and 300 mmol/L normal or patient's fibrinogen was incubated for 30 minutes at 37°C. To each sample, 20 pL of antihuman fibrinogen antibody (0.2%) was added, and the immune complexes formed at 30 minutes of incubation at 22°C were precipitated with 50 pL of protein A-Sepharose (Pharmacia, Uppsala, Sweden). After washing three times with TBS-BSA-Tween-A, the precipitate was analyzed for the radioactivity on a y-counter (Auto Well Gamma System, ARC-600; Aloca, Tokyo, Japan), and the bound thrombin was calculated for each sample.
The binding of thrombin to the isolated and insolubilized FPA. A fraction of the patient's fibrinogen (0.2 mL) diluted to 4 mg/mL (12.5 pmol/L) with phosphate-buffered saline (PBS) containing 25 KIU/mL aprotinin, was clotted with 0.05 mL of 1 U/mL ancrod at 37°C. After 2 hours of incubation, the samples were heattreated for 10 minutes at 100°C and the clot-liquor was harvested by centrifugation for IO minutes at 12,000 rpm. One-milliliter fractions of the normal and abnormal FPA apecies were separately collected by applying 200 pL of the clot-liquor to reverse-phase HPLC using a Cosmosil 5C18P column (4.6 X 150 mm) with a gradient from 0% to 50% acetonitrile in 0.1% trifluoroacetic acid (TFA) in 100 minutes at a flow rate of 0.5 mL/min. Fifty-microliter aliquots of each FPA species (2 pmol/L) were coupled to microtiter wells using a peptide-coating kit (Takara Biochemicals, Tokyo, Japan). The '251-labeled bovine thrombin (750 nmol/L; specific activity, 1.2 X IO6 cpm/pg) was diluted to give 3 to 120 nmol/L with 50 mmol/L Tris-HC1, pH 7.4, containing 100 mmol/L NaCl, 2% BSA, and 0.01% Tween 80 (TBS-BSA-Tween-B); 50 pL each of these diluted thrombin solutions was added to the FPA-conjugated microtiter wells. After 30 minutes at 22"C, the microtiter wells were washed three times with TBS-BSA-Tween-B and analyzed for the radioactivity on a y-counter, and the bound thrombin was calculated.
The normal and the abnormal FPA species derived from the ancrod-clotted patient's fibrinogen (see the lower panel of Fig 2, peaks 1 and 2 , respectively) were Amino acid sequence analysis.
analyzed for the primary sequence using a gas-phase sequenator, model 470A protein sequencer connected to a model 120A PTH analyzer (Applied Biosystems Japan, Tokyo, Japan) and model SP 4270 integrator (Spectra-Physics, San Jose, CA), essentially as described elsewhere?* The A a chain was separatedI6 and analyzed for the first 13 cycles.
Description of thepatient. The patient was a 14-year-old female with a mild hemorrhagic diathesis of easy bruising and recurrent purpura since childhood. As summarized in Table I , the thrombin time was prolonged in the patient's plasma both in the absence and the presence of calcium as compared with the normal control. The fibrinogen level in the patient's plasma was markedly reduced as determined by the thrombin time method of C l a u~s~~ but normal by the turbidimetric measurement. Similar results were obtained for her father but not for her mother, indicating that the patient may have had a congenitally abnormal fibrinogen transmitted from her father. The prothrombin time and the activated partial thromboplastin time were both slightly prolonged, namely, 77% of normal for the former and 42.6 seconds (normal, 27 to 40 seconds) for the latter. Besides bruising, which had been frequently observed, delayed healing of the site of an insect bite was noted. However, no clinical manifestations of bleeding or thrombotic tendencies were observed in her father.
RESULTS
The subunit structure and profiles of cross-linking mediated by activated factor XI11 and those of plasmic degradation were essentially identical with those of normal fibrinogen on sodium dodecyl sulfate-polyacrylamide gel electrophoresis analyses (profiles not shown).
However, the thrombin time was substantially prolonged both in the absence and the presence of calcium, but the ancrod time was normal as compared with normal fibrinogen ( Table 2 ). The thrombin-clotted patient's fibrin gels formed at 60 minutes of incubation at 37°C were rather fragile and appeared to be transparent, whereas the ancrodclotted patient's fibrin gels were apparently identical with the ancrod-clotted normal fibrin gels (Fig 1) . However, the thrombin-clotted fibrin gels became gradually solid and turbid and, eventually, indistinguishable from the control clots on further incubation.
HPLC analysis of FPA released from the patient's fibrinogen after 2 hours of incubation with thrombin and ancrod showed that the amounts of the normal FPA species (peaks 1 and 1' in Fig 2) were reduced to nearly half as much as the FPA species in the normal sample, and that additional peaks 2 and 2' newly arose in the patient's samples. These findings suggested that the patient's fibrinogen was most likely to be a heterozygous dysfibrinogen with a substitution of an amino acid(s) to a more basic one(s) in the FPA part of the molecule. The FPB species in the patient's sample a p peared to be identical with those ofthe normal control (peak 3 in the upper and lower panels in Fig 2. respectively) .
HPLC analysis of the timed release of the normal and abnormal FPA species from the patient's fibrinogen by thrombin also showed that the normal FPA species was nearly half as much as the FPA released from the normal control and that the release of the abnormal FPA species was distinctly delayed and reduced (Fig 3) . Although not depicted in Fig 3, the release of FPB from the patient's fibrinogen appeared to be slightly delayed but may not have been abnormal, considering its partial dependency on the polymerization of fibrin monomers deprived of FPAS.~.~' When fibrin monomers were prepared after sufficiently long incubation with thrombin (2 hours at 37°C and subsequently 22 hours at 22°C) and analyzed for aggregation, the profiles were substantially normal (profiles not shown), indicating that the aberrant FPA had also been cleaved by thrombin and thus the fibrin part of the molecule was indistinguishable from the normal molecule. The ancrod-clotted fibrin monomers harvested at 2 hoursofincubation at 37°C gave normal aggregation profiles, indicating that FPA had been cleaved efficiently by this enzyme.
The aberrant and the normal FPA species released by ancrod (peaks 1 and 2, respectively, in the patient's sample in Fig 2) were collected and analyzed for the amino acid sequence. The peak 1 peptide gave an amino acid sequence exactly for the normal FPA. ie. Ala-AspSer-Gly-Glu-GlyAsp-Phe-Leu-Ala-Glu-Gly-Gly-Gly-Val-Arg, but the peak 2 peptide was found to have a Gly residue at cycle 1 1 as italicized, ie. Ala-Asp-Ser-GIy-GIu-GIy-Asp-Phe-LeuAla-G/j7-Gly-Gly-Gly-Val-Arg. indicating that the Glu at position I 1 had been replaced by a Gly in the aberrant FPA. This result was confirmed by sequence analysis of the amino-terminal I3 cycles ofthe patient's fibrinogen-derived An chain, in which both Glu and Gly were identified at cycle I I with nearly identical recovery rates (Table 3 ). Thus. the patient's fibrinogen was found to be heterozygous for the abnormality of the An chain that has a point mutation of a Gly for the Glu at position 1 1.
The Glu-I I of the An chain of fibrinogen has recently been proposed to participate in the binding with thrombin by forming a salt bridge between its side chain carboxyl group and the guanidino group of Arg-I73 of thrombin.'*'' Indeed, the amount of '251-DIP-thrombin found to bind to the patient's fibrinogen in solution was nearly halfas much as that found to bind to normal fibrinogen (Fig 4) . Binding of '251-thrombin to the abnormal FPA species conjugated to microtiter wells was also decreased as compared with that to the normal FPA species, but was not totally defective ( Fig  5) .
DISCUSSION
In this communication. we have Characterized a new type of A n Glu-I I to Gly substitution in a hereditary abnormal fibrinogen with delayed release of FPA by thrombin from the abnormal An chain. Because of this amino acid substitution, affinity for thrombin was reduced, as evidenced by significantly decreased binding of '251-DIP-thrombin to the patient's fibrinogen (Fig 4) and '2SI-n-thrombin to the aberrant FPA isolated therefrom (Fig 5) . Because the ancrod times and release of the aberrant FPA by ancrod were all normal, the prolonged thrombin times and delayed release ofthe aberrant FPA by thrombin could be accounted for by the decreased binding with thrombin (Tables 1 and 2 , and Figs 2 and 3, respectively) .
It has recently been proposed that the side chain carboxyl group of An Glu-l I of human fibrinogen forms a salt bridge with the guanidino group of Arg-I73 of bovine and human n-thrombins on the basis of crystallographic analyses using analogsofFPA itselfand synthetic Aa(7-16) and (7-20) residue peptides.'.'' Thus, the mutation of this Glu residue to a neutral aliphatic amino acid Gly must have resulted in lack of the salt bridge formation with Arg-173 of thrombin. It is suggested that the Glu-l 1 residue contributes to the stabilization of the local n-helical conformation via a hydrogen bond formed between its amide nitrogen and the main chain carboxyl oxygen of An Asp-7, as determined by crystallographic analysis.9+'' It has also been suggested that Glu-1 1 is involved in a type I1 @-turn that would bring about the chain reversal within residues Leu-9 to Gly-14 in the normal FPA segment.' The Glu-l 1 to Gly substitution may disrupt the stabilized helical conformation comprising the Aa (7-10) residues or the type I1 @-turn, or both, thereby leading to delayed thrombin-catalyzed cleavage of FPA. However, the former possibility appears to be still controversial on the basis of a recent report that the Aa Asp-7 to Asn substitution identified in an abnormal fibrinogen, fibrinogen Lille, would not significantly affect the stabilized local conformation as determined by kinetics and NMR studies using the synthetic mutant and wild-type Aa (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) peptides." On the other hand, the chain reversal partly induced by the /?-turn involving Glu-1 1 and Gly-12 residues seems to be impaired in a hereditary mutant fibrinogen
Rouen with an Aa Gly-12 to Val substitution, and thus the thrombin-catalyzed FPA cleavage was significantly af- fected.' However, in the case of Mitaka 11-type Aa chain, delayed thrombin-catalyzed cleavage of the Arg-Gly bond could be accounted for largely, if not totally, by significantly reduced affinity for thrombin of the FPA part of the molecule either because of the inability to form a salt bridge with Arg-173 of thrombin or the disruption of the type I1 @-turn, or both. In addition to the Glu-ll residue. other amino 
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NlWA ET AL ---acids in the FPA segment must also be involved in the interaction with thrombin in one way or a n~t h e r ,~'~~~' *~* as implicated in the partially impaired binding ofthrombin to the abnormal ITA.
The Aa Glu-1 1 residue appears to be strongly conserved among the mammalian fibrinogens with Ala appearing in two species (rat and guinea pig) and possibly Asp in one (pronghorn) so far studied.9233 Instead, the former species with an Ala at position 1 1 have a Glu residue at position 9 (guinea pig) or position 10 (rat). Apart from the mammalian fibrinogens, the stumpy tailed lizard (Truchydosaurus rugosus) fibrinogen has been shown to have a Gly residue at the P6' site corresponding to position 1 1 of the human fibrinogen A a -~h a i n .~~ Interestingly, this Gly residue is preceded by two Glu residues. Therefore, it seems to be interesting to know whether the Glu residues present in the FPA part of fibrinogen in these species could be appropriately fitted into the local conformation that would allow them to form the putative salt bridge with Arg-173 of a-thrombin as well.
Besides these Aa-chain-involved interactions with thrombin, fibrinogen may also interact with thrombin at other parts of the molecule, as exemplified by defective thrombin binding in two structurally elucidated hereditary homozygous dysfibrinogens, New York I with a deletion of the BP (9-72) residue segment34 and Naples I with a BP Ala-68 to Thr sub~titution.~~ Interestingly, they were both associated with thrombophilia most probably caused by defective localization of thrombin to the fibrin clots. In fibrinogen Mitaka 11, the affected thrombin binding site was found to reside in the abnormal FPA, but not in the fibrin part of the molecule, and, therefore, the localization of thrombin to fibrin must have taken place normally in this dysfibrinogen. Conversely, a mild bleeding tendency was noted in the propositus, which may have been related to the delayed release of FPA.
Thus, the functional abnormalities of fibrinogen and their relevance to a mild bleeding tendency observed in fibrinogen Mitaka I1 seem to provide useful pieces of information for the better understanding of the molecular basis for the fibrinogen-thrombin interactions. 
